69 related articles for article (PubMed ID: 16101282)
1. Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase.
Sheth PR; Watowich SJ
Biochemistry; 2005 Aug; 44(33):10984-93. PubMed ID: 16101282
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
3. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
5. Oligomerization-dependent changes in the thermodynamic properties of the TPR-MET receptor tyrosine kinase.
Hays JL; Watowich SJ
Biochemistry; 2004 Aug; 43(32):10570-8. PubMed ID: 15301554
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
7. Oligomerization-induced modulation of TPR-MET tyrosine kinase activity.
Hays JL; Watowich SJ
J Biol Chem; 2003 Jul; 278(30):27456-63. PubMed ID: 12711601
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
9. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
Sridhar SC; Miranti CK
Oncogene; 2006 Apr; 25(16):2367-78. PubMed ID: 16331263
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.
Mak HH; Peschard P; Lin T; Naujokas MA; Zuo D; Park M
Oncogene; 2007 Nov; 26(51):7213-21. PubMed ID: 17533376
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
12. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
13. Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells.
Hui AY; Meens JA; Schick C; Organ SL; Qiao H; Tremblay EA; Schaeffer E; Uniyal S; Chan BM; Elliott BE
J Cell Biochem; 2009 Aug; 107(6):1168-81. PubMed ID: 19533669
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling.
Jeffers MF; Vande Woude GF
Oncogene; 1999 Sep; 18(36):5120-5. PubMed ID: 10490849
[TBL] [Abstract][Full Text] [Related]
15. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
16. Insulin receptor kinase-independent signaling via tyrosine phosphorylation of phosphatase PHLPP1.
Zhang M; Riedel H
J Cell Biochem; 2009 May; 107(1):65-75. PubMed ID: 19277985
[TBL] [Abstract][Full Text] [Related]
17. [The role of protein tyrosine phosphatases Shp-2 involved in the formation of the neuromuscular junction].
Zhao XT; Zhang Z
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1052-6. PubMed ID: 16784710
[TBL] [Abstract][Full Text] [Related]
18. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
19. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
[TBL] [Abstract][Full Text] [Related]
20. K252a inhibits the oncogenic properties of Met, the HGF receptor.
Morotti A; Mila S; Accornero P; Tagliabue E; Ponzetto C
Oncogene; 2002 Jul; 21(32):4885-93. PubMed ID: 12118367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
